The Fool Looks Ahead

There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come.

Monday
The trading week begins with WD-40 (Nasdaq: WDFC  ) reporting its latest quarterly results on Monday.

Analysts see the company behind the namesake lubricant and other home and industrial essentials earning $0.61 a share, well ahead of the $0.47 it earned a year earlier.

Tuesday
The market is quiet ahead of earnings season, which kicks in the following week, but Tuesday won't be completely silent. VOXX (Nasdaq: VOXX  ) is one of a handful of companies reporting this week. Wall Street's banking on the consumer-electronics company to crank out a profit of $0.10 a share.

Wednesday
Marriott (NYSE: MAR  ) spun off its timeshare business late last year, so Wednesday's quarterly report can't be exactly compared with the quarter it posted a year ago, but the hospitality giant is expected to post a healthy quarterly profit.

Thursday
Resources Connection
(Nasdaq: RECN  ) steps up on Thursday. The professional-services firm provides business leaders with the tools to execute internal initiatives. Business services and consulting are often good gauges for corporate activity. In that case, it's probably a good thing that analysts see strong bottom-line growth here.

Friday
The final trading day of the week is usually quiet, and it won't be any different this time around. A few financial-services providers will be checking in, including Webster Bank parent company Webster Financial (NYSE: WBS  ) .

Banking may not seem like a very compelling place to invest these days, but the pros see Webster posting healthy earnings growth.

Check that calendar
If you like to stay on top of what happens next -- and I'm guessing you do, because you're reading this article -- how about checking out The Motley Fool's top stock for 2012? It's a free report, but only for a limited time, so check it out now.

The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Longtime Fool contributor Rick Munarriz calls them as he sees them. He owns no shares in any of the stocks in this story and is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 07, 2012, at 7:21 PM, MrSinnister wrote:

    When will Discovery Labs (DSCO) finally get some love? I mean they have 2 FDA approved products that go into distribution in the 4Q, with the FDA approval coming in March. They only have 43 million outstanding shares, with a current market cap of 125M which nearly multiplies with every 10 cent increase. They are going to distribute a drug for Respiratory Distress Syndrome for infants in the US and European markets, and they have TREMENDOUS upside, already up 60 percent on the year. Add to that two more drugs awaiting approval, Aeroserf, that is in a collaboration with Batelle to get streamlined and fine-tuned and Surfaxin LS, a liquid version of their already FDA-approved drug Surfaxin. How this stock stays in the 2 range is amazingly shortsighted.

    Value of Surf LS + Afectair: 275million

    Shares O/S: 43mil

    Tell me why we can't see $40+/share with DSCO. Note that my sell target is below this, but I expect the stock to soar once it gains momentum. Imagine that liquid surfaxin penetrates the market quickly and gets great reviews by practicing docs (which it should). Surf LS will be even better. And Aerosurf even better after that.

    Facts:

    1. one approved device

    2. one approved drug

    3. $40 million in cash

    4. no debts

    5. no preferred stocks

    6. no impending warrants (outside of the 5yr 5M at 2.80)

    8. exclusive rights

    9. excellent pipeline

    10. Newly partnered (Batelle for R&D)

    11. MAA approval soon

    12. New device new drug launch soon

    13. Mkt Cap 128 million ???

    At 3 times sales, this is already $400 million firm, and that is $10 PPS. DSCO === Hidden Gem.

  • Report this Comment On November 25, 2013, at 12:27 PM, rosiew wrote:

    Timeshares are never a good investment. You can only use them for a certain time each year, and the upkeep payments on them are not worth it. When you go to sell them, you never get the price you paid. In the long run you'd be better off renting places in different locations each vacation. You aren't locked into one place that way:

    http://www.timesharescam.com/blog/58-is-timeshare-a-good-inv...

Add your comment.

DocumentId: 1935779, ~/Articles/ArticleHandler.aspx, 4/19/2014 6:09:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.


Advertisement